Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239353 | 0.82 | LPL (0.44) | GRM2JAK2LPLLIPG | |
| SCHEMBL552986 | 0.81 | PRMT6 (0.40) | CYP11B2FFAR1GSK3B | |
| SCHEMBL16196348 | 0.75 | CYP11B2 (0.51) | CYP11B2CYP11B1RIPK2PIK3CAMTOR | |
| SCHEMBL23242460 | 0.75 | LIPG (0.43) | LPLLIPG | |
| SCHEMBL552345 | 0.75 | KDM4E (0.47) | — | |
| SCHEMBL17184781 | 0.74 | CHRNB2 (0.43) | FFAR1LPLLIPG | |
| SCHEMBL15885252 | 0.72 | FFAR1 (0.44) | FFAR1 | |
| SCHEMBL17108792 | 0.71 | ACHE (0.41) | FFAR1LPLLIPG | |
| SCHEMBL23242449 | 0.71 | LPL (0.43) | LPLLIPG | |
| SCHEMBL30629583 | 0.70 | PRMT5 (0.33) | CYP11B2GRM2PRMT5WDR77PER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745289-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20160108026-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108026-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, HSD11B1 | CYP11B2 5/4885CYP11B1 2/4885RIPK2 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.